Divi's Laboratories Limited

BSE:532488 Stock Report

Market Cap: ₹1.6t

Divi's Laboratories Valuation

Is 532488 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532488 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.31k
Fair Value
351.1% overvalued intrinsic discount
27
Number of Analysts

Below Fair Value: 532488 (₹5913.85) is trading above our estimate of fair value (₹1310.91)

Significantly Below Fair Value: 532488 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532488?

Key metric: As 532488 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 532488. This is calculated by dividing 532488's market cap by their current earnings.
What is 532488's PE Ratio?
PE Ratio85.5x
Earnings₹18.36b
Market Cap₹1.57t

Price to Earnings Ratio vs Peers

How does 532488's PE Ratio compare to its peers?

The above table shows the PE ratio for 532488 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average66.6x
SYNGENE Syngene International
68.2x21.9%₹328.9b
INDGN Indegene
41.8x17.5%₹155.9b
SAILIFE Sai Life Sciences
120.4xn/a₹149.0b
AKUMS Akums Drugs and Pharmaceuticals
35.9x21.0%₹99.6b
532488 Divi's Laboratories
85.5x23.8%₹1.6t

Price-To-Earnings vs Peers: 532488 is expensive based on its Price-To-Earnings Ratio (85.5x) compared to the peer average (66.6x).

Price to Earnings Ratio vs Industry

How does 532488's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
532488 85.5xIndustry Avg. 33.4xNo. of Companies8PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 532488 is expensive based on its Price-To-Earnings Ratio (85.5x) compared to the Asian Life Sciences industry average (33.4x).

Price to Earnings Ratio vs Fair Ratio

What is 532488's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532488 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio85.5x
Fair PE Ratio50.6x

Price-To-Earnings vs Fair Ratio: 532488 is expensive based on its Price-To-Earnings Ratio (85.5x) compared to the estimated Fair Price-To-Earnings Ratio (50.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 532488 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹5,913.85
₹5,570.85
-5.8%
18.2%₹6,983.00₹3,758.00n/a27
Jan ’26₹6,070.95
₹5,484.14
-9.7%
18.6%₹6,983.00₹3,590.00n/a28
Dec ’25₹6,171.05
₹5,484.14
-11.1%
18.6%₹6,983.00₹3,590.00n/a28
Nov ’25₹5,901.00
₹4,630.74
-21.5%
19.7%₹6,850.00₹3,000.00n/a27
Oct ’25₹5,423.80
₹4,466.81
-17.6%
16.7%₹5,740.00₹3,000.00n/a27
Sep ’25₹5,093.40
₹4,466.81
-12.3%
16.7%₹5,740.00₹3,000.00n/a27
Aug ’25₹4,921.60
₹3,951.96
-19.7%
15.0%₹4,767.00₹2,644.00n/a27
Jul ’25₹4,599.90
₹3,911.00
-15.0%
14.7%₹4,767.00₹2,643.00n/a27
Jun ’25₹4,309.95
₹3,901.64
-9.5%
14.7%₹4,767.00₹2,643.00n/a28
May ’25₹4,000.15
₹3,491.50
-12.7%
15.1%₹4,720.00₹2,541.00n/a26
Apr ’25₹3,567.65
₹3,468.92
-2.8%
15.0%₹4,720.00₹2,541.00n/a24
Mar ’25₹3,478.90
₹3,452.72
-0.8%
14.9%₹4,720.00₹2,541.00n/a25
Feb ’25₹3,654.60
₹3,400.60
-7.0%
15.9%₹4,720.00₹2,344.00n/a25
Jan ’25₹3,912.75
₹3,346.48
-14.5%
16.1%₹4,720.00₹2,344.00₹6,070.9525
Dec ’24₹3,792.35
₹3,355.27
-11.5%
15.8%₹4,720.00₹2,344.00₹6,171.0526
Nov ’24₹3,344.80
₹3,415.36
+2.1%
15.8%₹4,720.00₹2,615.00₹5,901.0025
Oct ’24₹3,764.75
₹3,427.29
-9.0%
16.1%₹4,720.00₹2,615.00₹5,423.8024
Sep ’24₹3,588.80
₹3,427.29
-4.5%
16.1%₹4,720.00₹2,615.00₹5,093.4024
Aug ’24₹3,638.80
₹3,173.96
-12.8%
15.3%₹4,720.00₹2,585.00₹4,921.6023
Jul ’24₹3,583.05
₹3,140.95
-12.3%
15.8%₹4,720.00₹2,585.00₹4,599.9022
Jun ’24₹3,524.75
₹3,122.48
-11.4%
16.0%₹4,720.00₹2,450.00₹4,309.9523
May ’24₹3,266.45
₹3,022.39
-7.5%
16.5%₹4,720.00₹2,380.00₹4,000.1523
Apr ’24₹2,825.75
₹2,998.70
+6.1%
16.9%₹4,720.00₹2,380.00₹3,567.6523
Mar ’24₹2,844.60
₹3,059.17
+7.5%
18.8%₹4,720.00₹2,380.00₹3,478.9024
Feb ’24₹3,355.85
₹3,587.54
+6.9%
14.4%₹4,720.00₹2,829.00₹3,654.6024
Jan ’24₹3,412.60
₹3,594.92
+5.3%
14.2%₹4,720.00₹2,829.00₹3,912.7524
Analyst Price Target
Consensus Narrative from 27 Analysts
₹5.57k
Fair Value
6.2% overvalued intrinsic discount
27
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 17:39
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Divi's Laboratories Limited is covered by 55 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.